Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
MIF-1 (Pro-Leu-Gly-NH₂, melanostatin) is an endogenous tripeptide, a C-terminal fragment of oxytocin. In research it is described as a positive allosteric modulator of dopamine D2/D4 receptors that crosses the blood–brain barrier. This listing is currently not for sale.
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Base cycle (day 1–5) | 10 mg subcutaneously, once daily, 5 consecutive days | Starting dose |
| Repeat cycle | 10 mg/day × 5 days after a 2-day to 1–2-week washout | , |
| Higher doses | 75 mg/day orally in some reports gave a weaker effect than the low dose | Maximum in this schedule (inverted-U curve) |
Share your experience
No reviews yet. Tell others what you think of this product.
MIF-1 (Pro-Leu-Gly-NH₂; melanostatin, MSH-release-inhibiting factor 1) is an endogenous tripeptide (Pro-Leu-Gly-NH₂, abbreviated PLG) formed by cleavage of the C-terminal fragment of oxytocin.
The best-documented pharmacology of MIF-1 is positive allosteric modulation of dopamine D2 and D4 receptors: the peptide binds a site distinct from the orthosteric pocket and enhances the receptor's response to dopamine. MIF-1 resists degradation in plasma and crosses the blood–brain barrier directly. It was first isolated as a factor that inhibits release of melanocyte-stimulating hormone (MSH) — hence the name “melanostatin”.
In preclinical work and small early clinical studies, MIF-1 and its peptidomimetics were examined in Parkinson's disease (levodopa potentiation) and depression. The evidence base is limited, largely old and mixed — mostly small 1970s–1990s studies and animal models, with no modern large randomised trials. MIF-1 is not an approved medicine and its clinical efficacy in humans is not established. A referenced review is in the monograph.
This listing is currently not for sale (coming soon). The batch specification and certificate of analysis (HPLC purity, mass confirmation by mass spectrometry) will be published before sales begin.
